Literature DB >> 18421647

[Results in otosurgically treated patients with acoustic neuroma. Part 1: Facial nerve function after translabyrinthine and middle fossa resection].

G Baier1, K Schwager, J Helms, R Hagen.   

Abstract

BACKGROUND: Regardless of all efforts to preserve a residual hearing, facial nerve function is still the primary issue for patients with acoustic neuromas. Since alternative methods like the gamma-knife treatment are of increasing importance, results after surgery have to be compared and discussed critically. PATIENTS: The results of 538 patients operated at the Dept. of Otolaryngology, Head and Neck Surgery, University of Wuerzburg between 1989 and 2004 are presented. 392 had surgery via a middle fossa, 146 via a translabyrinthine approach.
RESULTS: Shortly after surgery 82.2 % of patients showed no facial palsy. 74 patients had an incomplete, 7 a complete paresis. After 12 months 144 of the patients operated on via middle fossa approach showed no palsy, 13 had an incomplete and one a complete paresis. Out of 76 patients operated on translabyrinthine approach 75 had no paresis, one had an incomplete, and no patient had a complete paresis. There was no difference between intrameatal tumors and tumors extending beyond the porus. Regular facial nerve function was seen in 93 %, postoperatively. Permanent paresis was seen in 0.4 % of cases.
CONCLUSION: Acoustic neuroma confined to the internal meatus or with minor extension into the cerebello-pontine angle (i. e. no contact to structures of the brain stem or vessels of the posterior fossa) are feasible for resection via a middle fossa or translabyrinthine approach. The possibility of hearing preservation combined with low morbidity and good results of facial nerve function makes these approaches the treatment of choice for this group of tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18421647     DOI: 10.1055/s-2007-995644

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  8 in total

1.  Outcome on hearing and facial nerve function in microsurgical treatment of small vestibular schwannoma via the middle cranial fossa approach.

Authors:  Christian Ginzkey; Matthias Scheich; Wilma Harnisch; Verena Bonn; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Robert Mlynski; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-22       Impact factor: 2.503

2.  [Vestibular schwannoma. Part 2: therapy, prognosis, and rehabilitation].

Authors:  W Maier; F Hassepaß; A Aschendorff; R Laszig
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

3.  Use of flexible CO₂ laser fiber in microsurgery for vestibular schwannoma via the middle cranial fossa approach.

Authors:  Matthias Scheich; Christian Ginzkey; Wilma Harnisch; Desiree Ehrmann; Wafaa Shehata-Dieler; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-04       Impact factor: 2.503

4.  [Hearing results after middle fossa removal of small (T1/T2) vestibular schwannomas].

Authors:  M Scheich; D Ehrmann-Müller; W Shehata-Dieler; R Hagen
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

Review 5.  [Value of different strategies in the treatment of vestibular schwannoma: therapeutic aspects and literature analysis].

Authors:  W Maier; T D Grauvogel; R Laszig; G J Ridder
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

6.  [Acoustic neuroma (vestibular schwannoma) therapy from an oto-rhino-laryngological perspective].

Authors:  K Schwager
Journal:  HNO       Date:  2011-01       Impact factor: 1.284

7.  How I Do It: The Role of Flexible Hand-held 2μ-Thulium Laser Fiber in Microsurgical Removal of Acoustic Neuromas.

Authors:  Luciano Mastronardi; Guglielmo Cacciotti; Raffaele Roperto; Maria Pia Tonelli; Ettore Carpineta
Journal:  J Neurol Surg B Skull Base       Date:  2017-02-08

8.  Management of CSF leakage after microsurgery for vestibular schwannoma via the middle cranial fossa approach.

Authors:  Matthias Scheich; Christian Ginzkey; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-09       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.